Zobrazeno 1 - 10
of 14
pro vyhledávání: '"The Overactive Bladder Questionnaire Short Form"'
Autor:
Chiara Cimmino, Andrea Braga, Maurizio Serati, Enrico Finazzi Agrò, Fabio Ghezzi, Chiara Scancarello, Anna Chiara Coluccia, Stefano Salvatore, Simona Cantaluppi
Publikováno v:
Minerva urology and nephrology. 73(6)
Background For women with overactive bladder (OAB), current guidelines recommend the use of urodynamic studies (UDS) only in complicated cases. This study aimed to investigate whether UDS can also be helpful in uncomplicated cases. Specific aims of t
Autor:
Jack Burks, Michael Chancellor, David Bates, Pierre Denys, Scott MacDiarmid, Victor Nitti, Denise Globe, Manuel Signori, Stacie Hudgens, Ib Odderson, Jalesh Panicker, Amy Perrin Ross
Publikováno v:
International Journal of MS Care. 15:182-192
Bladder symptoms such as urinary urgency, frequency, and incontinence are common in people with multiple sclerosis (MS). These symptoms, which often result from neurogenic detrusor overactivity (NDO), can have a major impact on patients' day-to-day l
Autor:
Elena Cattoni, Fabio Ghezzi, Stefano Uccella, Stefano Salvatore, Gabriele Siesto, Antonella Cromi, Andrea Braga, Paola Sorice, Maurizio Serati
Publikováno v:
Urology. 82:1044-1048
Objective To evaluate the outcomes of women treated with Solifenacin 5 mg once a day for overactive bladder (OAB) to identify the factors associated with the risk of treatment failure. Methods Women with OAB symptoms for at least 3 months were consid
Autor:
Tracy L. Nolen, Sandip P. Vasavada, Lily A. Arya, Halina M. Zyczynski, Susan Meikle, Yuko M. Komesu, Shawn A. Menefee, Dennis Wallace, Holly E. Richter, Deborah L. Myers, W. Thomas Gregory, Cindy L. Amundsen
Women with refractory urgency urinary incontinence are treated with sacral neuromodulation and onabotulinumtoxinA with limited comparative information.To assess whether onabotulinumtoxinA is superior to sacral neuromodulation in controlling refractor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850ee38c89722aae1f1a3d4aecf8d3be
https://europepmc.org/articles/PMC5399419/
https://europepmc.org/articles/PMC5399419/
Autor:
Serati, Maurizio, LEONE ROBERTI MAGGIORE, Umberto, Sorice, Paola, Cantaluppi, Simona, Agrò, Enrico Finazzi, Ghezzi, Fabio, Publication Committee Of The Italian Society Of Urodynamics, Null
Publikováno v:
Obstetrical & Gynecological Survey. 72:160-161
No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in OAB patients. Hence, the primary objective of this study was to evaluate the efficacy of mirabegron in treatment-naive patients in comparison with tho
Autor:
Karin S. Coyne, Christopher R. Chapple, Chris C. Sexton, Zoe Kopp, Ian Milsom, Caty Ebel-Bitoun
Publikováno v:
BJU International. 108:1459-1471
Objective • To examine the prevalence and burden of overactive bladder (OAB) with bother in the UK and Sweden compared to OAB without bother and no/minimal OAB/lower urinary tract (LUTS) symptoms, respectively. Patients and methods • A cross-sect
Autor:
Wolfgang Loidl, Tim Larner, Ulrich Witzsch, Andrea Tubaro, Neil Barber, Martin Schostak, Andrew C. Thorpe, Herman Roelink, Jens-Uwe Stolzenburg, Nirjan-Kumar Gogoi, Moritz Hamann, Stuart L. Graham, Filip Ameye, Richard Hindley, Antony C. P. Riddick, Alexander Bachmann, Nitin Shrotri, Gordon Muir, Frank C H d'Ancona, Helmut H. Knispel, Kurt Miller, Rolf Muschter, Christian Saussine, Franck Bruyère, Carlos Capitán, Marc-Oliver Grimm, Sascha Pahernik, James Andrew Thomas, Joan Benejam
Background The GOLIATH study is a 2-yr trial comparing transurethral resection of prostate (TURP) to photoselective vaporization with the GreenLight XPS Laser System (GL-XPS) for the treatment of benign prostatic obstruction (BPO). Noninferiority of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e6e330b0d3e06018f592777a9eca67f
http://hdl.handle.net/11573/958588
http://hdl.handle.net/11573/958588
Publikováno v:
Korean Journal of Urology
Purpose: We attempted to examine the correlation between metabolic syndrome and lower urinary tract symptoms (LUTS) in the aspect of gender-specific medicine. Materials and Methods: A total of 922 patients participating in a health examination comple
Autor:
Scott Haughie, Peter M. Ellis, Nihad Tamimi, Anna Crossland, Francois A. Giuliano, Janice Lamb
Publikováno v:
BJU international. 106(5)
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVES To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor, UK-369,003 modified release (MR), for the treatment of storage lower urinary tract symptoms (LUTS) in men with
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.